Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALVO
Upturn stock ratingUpturn stock rating

Alvotech (ALVO)

Upturn stock ratingUpturn stock rating
$9.12
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ALVO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $17.9

1 Year Target Price $17.9

Analysts Price Target For last 52 week
$17.9Target price
Low$7.35
Current$9.12
high$13.7

Analysis of Past Performance

Type Stock
Historic Profit 2.5%
Avg. Invested days 36
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.83B USD
Price to earnings Ratio 24.7
1Y Target Price 17.9
Price to earnings Ratio 24.7
1Y Target Price 17.9
Volume (30-day avg) 4
Beta 0.19
52 Weeks Range 7.35 - 13.70
Updated Date 06/29/2025
52 Weeks Range 7.35 - 13.70
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.37

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 16.42%
Operating Margin (TTM) 7.97%

Management Effectiveness

Return on Assets (TTM) 7.02%
Return on Equity (TTM) -

Valuation

Trailing PE 24.7
Forward PE 45.45
Enterprise Value 4015455887
Price to Sales(TTM) 4.81
Enterprise Value 4015455887
Price to Sales(TTM) 4.81
Enterprise Value to Revenue 6.86
Enterprise Value to EBITDA 28.92
Shares Outstanding 309305984
Shares Floating 100126591
Shares Outstanding 309305984
Shares Floating 100126591
Percent Insiders 63.44
Percent Institutions 6.44

Analyst Ratings

Rating 2
Target Price 17.9
Buy -
Strong Buy 2
Buy -
Strong Buy 2
Hold 2
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Alvotech

stock logo

Company Overview

overview logo History and Background

Alvotech is a biopharmaceutical company focused on developing and manufacturing biosimilar medicines. Founded in 2012, it aims to improve patient access to affordable biological treatments. Alvotech merged with Oaktree Acquisition Corp. II in 2022, becoming publicly listed.

business area logo Core Business Areas

  • Biosimilar Development: Developing biosimilar versions of major biologic drugs. Focused on oncology, immunology, and ophthalmology.
  • Manufacturing: Operates its own manufacturing facilities to produce biosimilar products.
  • Commercialization: Partners with other pharmaceutical companies for commercialization and distribution of its products.

leadership logo Leadership and Structure

Robert Wessman serves as Chairman and CEO. The company has a structured management team overseeing research, development, manufacturing, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • AVT02 (adalimumab biosimilar): Biosimilar to Humira (adalimumab). Targeting inflammatory diseases. Competitors include Amgen's Amjevita, Boehringer Ingelheim's Cyltezo, and others. Alvotech has faced legal challenges regarding patent infringement.
  • AVT04 (ustekinumab biosimilar): Biosimilar to Stelara (ustekinumab). Targeting inflammatory diseases. Still in development. Competitors include Amgen and other biosimilar developers.

Market Dynamics

industry overview logo Industry Overview

The biosimilar market is experiencing significant growth due to patent expirations of originator biologics and increasing demand for lower-cost treatment options. High barriers to entry exist due to complex manufacturing and regulatory requirements.

Positioning

Alvotech aims to be a leading player in the global biosimilar market by developing and commercializing a portfolio of high-quality, affordable biosimilar products. They are focusing on major markets and partnering to expand their reach.

Total Addressable Market (TAM)

The global biosimilars market is projected to reach over $100 billion by 2030. Alvotech's positioning is to capture a significant share of this growing market by focusing on high-value biosimilars and strategic partnerships.

Upturn SWOT Analysis

Strengths

  • Strong focus on biosimilar development
  • Advanced manufacturing capabilities
  • Strategic partnerships for commercialization
  • Experienced management team
  • Focus on high value biosimilars

Weaknesses

  • Reliance on partnerships for commercialization
  • Dependence on successful regulatory approvals
  • Limited operating history as a publicly listed company
  • Competition from established pharmaceutical companies
  • Ongoing patent litigation

Opportunities

  • Growing biosimilar market
  • Patent expirations of major biologics
  • Expansion into new markets
  • Development of new biosimilars
  • Increasing adoption of biosimilars by healthcare providers

Threats

  • Intense competition
  • Patent litigation
  • Regulatory hurdles
  • Price erosion in the biosimilar market
  • Slower than expected biosimilar adoption

Competitors and Market Share

competitor logo Key Competitors

  • AMGN
  • PFE
  • BMY
  • VTRS

Competitive Landscape

Alvotech competes with established pharmaceutical companies in the biosimilar market. Its advantage lies in its focus on biosimilars and manufacturing capabilities. Its disadvantages include reliance on partnerships and smaller scale.

Major Acquisitions

Strada Biopharma

  • Year: 2020
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: Alvotech obtained exclusive rights in the U.S. to commercialize a portfolio of biosimilar candidates, including biosimilars to Humira, Stelara, and Eylea.

Growth Trajectory and Initiatives

Historical Growth: Alvotech's historical growth is marked by R&D progress and strategic partnerships. Revenue growth has been driven by initial product launches.

Future Projections: Future growth is projected based on the launch and adoption of its biosimilar portfolio. Analyst estimates suggest substantial revenue growth as more products reach the market.

Recent Initiatives: Recent initiatives include securing regulatory approvals for AVT02, expanding manufacturing capacity, and strengthening partnerships.

Summary

Alvotech is a biopharmaceutical company with potential in the growing biosimilars market. While it faces challenges related to competition, patent litigation, and regulatory approvals, its strategic partnerships and focus on high-value biosimilars position it for long-term growth. The company's future success hinges on its ability to successfully navigate these challenges and commercialize its product pipeline. Alvotech is still in early stages of growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Actual results may vary significantly from projections due to market conditions and other factors.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Alvotech

Exchange NASDAQ
Headquaters -
IPO Launch date 2022-06-16
CEO, Founder & Executive Chairman Mr. Robert Wessman
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 1012
Full time employees 1012

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.